Studies of amplification in rhabdomyosarcoma
Studies of amplification in rhabdomyosarcoma
批准号:
8938081
负责人:
Frederic Barr
金额:
$41.07万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
12q13-q1413q141p362p24BehaviorBiologicalBiological AssayCDK4 geneCandidate Disease GeneCell CountCell CycleCell LineCellsChemicalsChildren&aposs Oncology GroupChromosomes, Human, Pair 12ClinicalCollaborationsComplementary DNACyclin-Dependent Kinase 4Cyclin-Dependent Kinase Inhibitor 2ADataDefectDoseEventFamilyFlow CytometryFluorescent in Situ HybridizationG1 ArrestGene ExpressionGenesGeneticGenetic TranscriptionGenomicsGoalsGrowthHeterogeneityIsopropyl ThiogalactosideLaboratoriesLaboratory miceMapsMessenger RNAMicroarray AnalysisMolecularMolecular ProfilingOncogene ProteinsOncogenicOther GeneticsPAX3 genePAX7 genePathogenesisPathologyPathway interactionsPredispositionProteinsProto-OncogenesRNARNA InterferenceReagentRecurrenceRhabdomyosarcomaRoleSimulateSpecimenTherapeutic InterventionTissue MicroarrayXenograft procedurebasecell growthdirected attentionoverexpressionprotein expressionresearch studysmall hairpin RNAtherapeutic targettumortumorigenesis
中文摘要
我们最近对横纹肌肉瘤(RMS)复发扩增的研究主要集中在12q13-Q14扩增,它优先出现在PAX3-FOXO1阳性的横纹肌肉瘤中的一小部分(25%),仅出现在PAX7-FOXO1阳性和融合阴性的一小部分横纹肌肉瘤中。我们以前的研究将最小扩增区域定位到0.55Mb区域,包含28个基因,包括CDK4原癌基因。在有和没有该扩增子的RMS肿瘤中的表达谱研究表明,在扩增的RMS肿瘤中,这些基因中的7个(包括CDK4)在RNA水平上持续过表达。然后,我们重点研究了CDK4基因,并通过与病理实验室的Svetlana Pack博士和Stephen Hewitt博士的合作,评估了CDK4蛋白表达和扩增状态之间的关系。两个RMS标本的组织微阵列(TMA)来自儿童肿瘤组。帕克博士使用荧光原位杂交探针来确定每个病例在TMA上的12q13-Q14扩增状态,休伊特博士使用免疫组织化学方法来评估这些病例中CDK4的蛋白表达。这些TMA研究的综合结果表明,12q13-q14扩增的病例表达高水平的CDK4蛋白,12号染色体额外拷贝的病例表达中等水平的蛋白质,而12q13-q14拷贝数正常的病例表达低蛋白水平。为了分析CDK4扩增的功能后果,将IPTG诱导的针对CDK4基因的shRNA导入Rh30细胞,该细胞系具有12q13-Q14扩增的融合阳性RMS系,并伴随着CDK4mRNA和蛋白的高水平表达。在Rh30细胞中诱导CDK4-shRNA结构导致CDK4的表达受到抑制。此外,这种CDK4表达的抑制与细胞生长缺陷有关,流式细胞术的特征是G1期停滞。在实验室小鼠的肿瘤发生研究中,在Rh30细胞中诱导CDK4 shRNA导致异种移植瘤形成的延迟。用可诱导CDK4shRNA对Rh30细胞的表达芯片分析表明,CDK4-Rb途径中E2F转录靶点和其他细胞周期相关基因的表达降低。在进一步的IPTG诱导的CDK4 shRNA构建物的实验中,在没有12q13-q14扩增的Rh41细胞系中诱导CDK4 shRNA也显示出类似的细胞生长抑制。这一发现提供了12q13-q14扩增或过度表达与CDK4抑制敏感性增加无关的初步证据。为了进一步分析这个问题,我们比较了五个融合阳性的RMS细胞株对CDK4/CDK6的选择性抑制剂LEE011(诺华公司)抑制生长的敏感性。用不同浓度的LEE011处理这五株细胞后,细胞数量呈剂量依赖性减少,CDK4-Rb通路靶标的表达也相应减少。CDK4和CDK6的表达水平与细胞对生长抑制的敏感性无关。尤其是,在Rh30中CDK4的高表达与较高的生长抑制敏感性无关。
英文摘要
Our recent studies of recurrent amplicons in rhabdomyosarcoma (RMS) focused on the 12q13-q14 amplicon, which occurs preferentially in a subset of PAX3-FOXO1-positive RMS (25% of cases) and only in a smaller subset of PAX7-FOXO1-positive and fusion-negative cases. Our previous studies localized the minimal region of amplification to a 0.55 Mb region containing 28 genes, including the CDK4 proto-oncogene. Expression profiling studies in RMS tumors with and without this amplicon showed that 7 of these genes (including CDK4) were consistently overexpressed at the RNA level in amplified RMS tumors. We then focused on the CDK4 gene and assessed the relationship between CDK4 protein expression and amplification status through a collaboration with Drs. Svetlana Pack and Stephen Hewitt of the Laboratory of Pathology. Two tissue microarrays (TMA's) of RMS specimens were obtained from the Children's Oncology Group. Dr. Pack used fluorescence in situ hybridization probes to determine 12q13-q14 amplification status in each case on the TMA, and Dr. Hewitt used an immunohistochemical approach to assess CDK4 protein expression in these cases. The combined results from these TMA studies indicated that cases with 12q13-q14 amplification expressed high levels of CDK4 protein, cases with extra copies of chromosome 12 expressed intermediate protein levels and cases with normal 12q13-q14 copy number expressed low protein levels. To analyze the functional consequences of CDK4 amplification, IPTG-inducible shRNA constructs targeted against the CDK4 gene were transduced into Rh30 cells, a fusion-positive RMS line with 12q13-q14 amplification and associated high level expression of CDK4 mRNA and protein. Induction of the CDK4-shRNA constructs in Rh30 cells resulted in inhibition of CDK4 expression. In addition, this inhibition of CDK4 expression was associated with defects in cell growth, characterized as a G1 arrest by flow cytometry. In tumorigenesis studies in laboratory mice, CDK4 shRNA induction in Rh30 cells resulted in a delay in xenograft formation. Expression microarray analysis of Rh30 cells with inducible CDK4 shRNA demonstrated decreased expression of genes in the CDK4-RB pathway, such as E2F transcriptional targets and other cell cycle-related genes. In further experiments with the IPTG-inducible CDK4 shRNA constructs, induction of CDK4 shRNA in the Rh41 cell line, which does not have 12q13-q14 amplification, also demonstrated similar decreases in cell growth. This finding provides initial evidence that 12q13-q14 amplification or overexpression is not associated with increased sensitivity to CDK4 inhibition. To further analyze this issue, we compared the sensitivity of five fusion-positive RMS cell lines to growth inhibition by LEE011 (Novartis), a selective inhibitor of CDK4/CDK6. Treatment of these five lines with a range of LEE011 concentrations resulted in a dose-dependent decrease in cell numbers and a corresponding decrease in expression of CDK4-RB pathway targets. There was no relationship between sensitivity to growth inhibition and the CDK4 or CDK6 expression levels in these cell lines. In particular, the high CDK4 expression in Rh30 was not associated with higher susceptibility to growth inhibition.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies of gene fusions in rhabdomyosarcoma
-
批准号:10486830
-
项目类别:
-
资助金额:$70.45万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:8349507
-
项目类别:
-
资助金额:$17.03万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:8763479
-
项目类别:
-
资助金额:$33.5万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Clinical Operations for Laboratory of Pathology
-
批准号:9556867
-
项目类别:
-
资助金额:$66.83万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of gene fusions in rhabdomyosarcoma
-
批准号:9153887
-
项目类别:
-
资助金额:$47.33万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of gene fusions in rhabdomyosarcoma
-
批准号:8763485
-
项目类别:
-
资助金额:$40.2万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:9556544
-
项目类别:
-
资助金额:$30.47万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:9153908
-
项目类别:
-
资助金额:$43.38万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:8553174
-
项目类别:
-
资助金额:$51.06万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:8938110
-
项目类别:
-
资助金额:$50.65万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of gene fusions in rhabdomyosarcoma
-
批准号:9343899
-
项目类别:
-
资助金额:$59.23万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Anatomic Pathology Residency Program
-
批准号:9556893
-
项目类别:
-
资助金额:$152.37万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Anatomic Pathology Residency Program
-
批准号:10703126
-
项目类别:
-
资助金额:$203.96万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:10926196
-
项目类别:
-
资助金额:$74.45万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:10014672
-
项目类别:
-
资助金额:$30.76万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:9343894
-
项目类别:
-
资助金额:$29.61万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:10486826
-
项目类别:
-
资助金额:$54.79万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:10486842
-
项目类别:
-
资助金额:$39.14万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Histology Core Laboratory
-
批准号:9556801
-
项目类别:
-
资助金额:$187.13万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:8763513
-
项目类别:
-
资助金额:$37.97万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
国内基金
海外基金
CTCF通过介导染色体13q14 基因组区异常构象促进视网膜母细胞瘤发生的机制研究
-
批准号:81802739
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:文旭洋
-
依托单位:
13q14染色体缺失通过下调miRNA表达参与多发性骨髓瘤血管新生
-
批准号:30700331
-
项目类别:青年科学基金项目
-
资助金额:17.0万元
-
批准年份:2007
-
负责人:孙春艳
-
依托单位: